Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Lippitz, Bodo E ^a   Harris, Robert A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Cytokines; IL 6; Interleukin 6; Paraneoplastic; Prognosis; Sweden

Indexed keywords

INTERLEUKIN 6;

CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; HUMAN; IMMUNOMODULATION; META ANALYSIS (TOPIC); METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84975859130     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1093722     Document Type: Review

References (165)

1. B.E.Lippitz. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218-28; PMID:23639322; http://dx.doi.org/10.1016/S1470-2045(12)70582-X
2. A.Mantovani, P.Allavena, A.Sica, F.Balkwill. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
3. S.I.Grivennikov, F.R.Greten, M.Karin. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025
4. L.Zitvogel, C.Tanchot, C.Granier, E.Tartour. Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2013; 2:e25444; PMID:24073383; http://dx.doi.org/10.4161/onci.25444
5. A.Mantovani, T.Schioppa, C.Porta, P.Allavena, A.Sica. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-22; PMID:16967326; http://dx.doi.org/10.1007/s10555-006-9001-7
6. G.Kaplanski, V.Marin, F.Montero-Julian, A.Mantovani, C.Farnarier. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24:25-9; PMID:12495721; http://dx.doi.org/10.1016/S1471-4906(02)00013-3
7. S.M.Hurst, T.S.Wilkinson, R.M.McLoughlin, S.Jones, S.Horiuchi, N.Yamamoto, S.Rose-John, G.M.Fuller, N.Topley, S.A.Jones. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14; PMID:11420041; http://dx.doi.org/10.1016/S1074-7613(01)00151-0
8. V.Marin, F.A.Montero-Julian, S.Gres, V.Boulay, P.Bongrand, C.Farnarier, G.Kaplanski. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 2001; 167:3435-42; PMID:11544336; http://dx.doi.org/10.4049/jimmunol.167.6.3435
9. T.Kishimoto, S.Akira, M.Narazaki, T.Taga. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54; PMID:7632928
10. T.Hirano, K.Yasukawa, H.Harada, T.Taga, Y.Watanabe, T.Matsuda, S.Kashiwamura, K.Nakajima, K.Koyama, A.Iwamatsu et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-6; PMID:3491322; http://dx.doi.org/10.1038/324073a0
11. E.Bettelli, Y.Carrier, W.Gao, T.Korn, T.B.Strom, M.Oukka, H.L.Weiner, V.K.Kuchroo. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16648838; http://dx.doi.org/10.1038/nature04753
12. P.R.Mangan, L.E.Harrington, D.B.O'Quinn, W.S.Helms, D.C.Bullard, C.O.Elson, R.D.Hatton, S.M.Wahl, T.R.Schoeb, C.T.Weaver. Transforming growth factor-β induces development of the T(H)17 lineage. Nature 2006; 441:231-4; PMID:16648837; http://dx.doi.org/10.1038/nature04754
13. M.Veldhoen, R.J.Hocking, C.J.Atkins, R.M.Locksley, B.Stockinger. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-89; PMID:16473830; http://dx.doi.org/10.1016/j.immuni.2006.01.001
14. A.Kimura, T.Kishimoto. Th17 cells in inflammation. Int Immunopharmacol 2011; 11:319-22; PMID:21035432; http://dx.doi.org/10.1016/j.intimp.2010.10.004
15. M.F.Neurath, S.Finotto. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22:83-9; PMID:21377916; http://dx.doi.org/10.1016/j.cytogfr.2011.02.003
16. W.Chen, W.Jin, N.Hardegen, K.J.Lei, L.Li, N.Marinos, G.McGrady, S.M.Wahl. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
17. M.C.Fantini, C.Becker, G.Monteleone, F.Pallone, P.R.Galle, M.F.Neurath. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J Immunol 2004; 172:5149-53; PMID:15100250; http://dx.doi.org/10.4049/jimmunol.172.9.5149
18. M.Fujimoto, M.Nakano, F.Terabe, H.Kawahata, T.Ohkawara, Y.Han, B.Ripley, S.Serada, T.Nishikawa, A.Kimura et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186:32-40; PMID:21106853; http://dx.doi.org/10.4049/jimmunol.0903314
19. S.Dominitzki, M.C.Fantini, C.Neufert, A.Nikolaev, P.R.Galle, J.Scheller, G.Monteleone, S.Rose-John, M.F.Neurath, C.Becker. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007; 179:2041-5; PMID:17675459; http://dx.doi.org/10.4049/jimmunol.179.4.2041
20. H.Schuett, M.Luchtefeld, C.Grothusen, K.Grote, B.Schieffer. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009; 102:215-22; PMID:19652871; http://dx.doi.org/10.1160/TH09-05-0297
21. Y.Fan, J.Ye, F.Shen, Y.Zhu, Y.Yeghiazarians, W.Zhu, Y.Chen, M.T.Lawton, W.L.Young, G.Y.Yang. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28:90-8; PMID:17519976; http://dx.doi.org/10.1038/sj.jcbfm.9600509
22. M.Ghazizadeh. Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 2007; 74:11-22; PMID:17384473; http://dx.doi.org/10.1272/jnms.74.11
23. S.Suzuki, S.Mita, H.Kamohara, K.Sakamoto, T.Ishiko, M.Ogawa. IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol 2001; 18:581-6; PMID:11179490
24. J.P.Herbeuval, E.Lelievre, C.Lambert, M.Dy, C.Genin. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 2004; 172:4630-6; PMID:15034082; http://dx.doi.org/10.4049/jimmunol.172.7.4630
25. D.M.Mosser, X.Zhang. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226:205-18; PMID:19161426; http://dx.doi.org/10.1111/j.1600-065X.2008.00706.x
26. A.B.Nixon, H.Pang, M.D.Starr, P.N.Friedman, M.M.Bertagnolli, H.L.Kindler, R.M.Goldberg, A.P.Venook, H.I.Hurwitz. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clin Cancer Res 2013; 19:6957-66; PMID:24097873; http://dx.doi.org/10.1158/1078-0432.CCR-13-0926
27. O.Tredan, I.Ray-Coquard, G.Chvetzoff, P.Rebattu, A.Bajard, S.Chabaud, D.Perol, C.Saba, F.Quiblier, J.Y.Blay et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011; 11:95; PMID:21406082; http://dx.doi.org/10.1186/1471-2407-11-95
28. S.Ramsey, M.Aitchison, J.Graham, D.C.McMillan. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int 2008; 102:125-9; PMID:18336617; http://dx.doi.org/10.1111/j.1464-410X.2008.07466.x
29. A.Duletic-Nacinovic, S.Stifter, B.Marijic, K.Lucin, T.Valkovic, D.Petranovic, N.Jonjic. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma. Tumori 2008; 94:511-7; PMID:18822687
30. L.Fayad, F.Cabanillas, M.Talpaz, P.McLaughlin, R.Kurzrock. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998; 30:563-71; PMID:9711918
31. S.Y.Suh, Y.S.Choi, C.H.Yeom, S.M.Kwak, H.M.Yoon, D.G.Kim, S.J.Koh, J.Park, M.A.Lee, Y.J.Lee et al. Interleukin-6 but not tumour necrosis factor-α predicts survival in patients with advanced cancer. Support Care Cancer 2013; 21:3071-7; PMID:23828393; http://dx.doi.org/10.1007/s00520-013-1878-4
32. A.E.Utech, E.M.Tadros, T.G.Hayes, J.M.Garcia. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012; 3:245-51; PMID:22648739; http://dx.doi.org/10.1007/s13539-012-0075-5
33. M.Grim-Stieger, M.Keilani, R.M.Mader, C.Marosi, M.Schmidinger, C.C.Zielinski, V.Fialka-Moser, R.Crevenna. Serum levels of tumour necrosis factor-α and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate–preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. Eur J Cancer Care (Engl) 2008; 17:454-62; PMID:18637115; http://dx.doi.org/10.1111/j.1365-2354.2007.00874.x
34. K.Heikkila, S.Ebrahim, A.Rumley, G.Lowe, D.A.Lawlor. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16:1155-9; PMID:17548678; http://dx.doi.org/10.1158/1055-9965.EPI-07-0093
35. M.Di Nisio, T.M.Niers, P.H.Reitsma, H.R.Buller. Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration. Cancer 2005; 104:2275-81; PMID:16216004; http://dx.doi.org/10.1002/cncr.21485
36. G.Mantovani, A.Maccio, C.Madeddu, L.Mura, E.Massa, M.C.Mudu, C.Mulas, M.R.Lusso, G.Gramignano, M.B.Piras. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med (Berl) 2001; 79:406-14; PMID:11466563; http://dx.doi.org/10.1007/s001090100234
37. G.Reynes, V.Vila, M.Martin, A.Parada, T.Fleitas, E.Reganon, V.Martinez-Sales. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011; 102:35-41; PMID:20607353; http://dx.doi.org/10.1007/s11060-010-0290-x
38. A.M.Tsimberidou, E.Estey, S.Wen, S.Pierce, H.Kantarjian, M.Albitar, R.Kurzrock. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113:1605-13; PMID:18683214; http://dx.doi.org/10.1002/cncr.23785
39. X.Thomas, C.Hirschauer, J.Troncy, D.Assouline, M.O.Joly, D.Fiere, E.Archimbaud. Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome. Leuk Lymphoma 1997; 24:291-300; PMID:9156658
40. H.Kita, Y.Shiraishi, K.Watanabe, K.Suda, K.Ohtsuka, Y.Koshiishi, T.Goya. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 2011; 17:454-60; PMID:21881374; http://dx.doi.org/10.5761/atcs.oa.10.01627
41. F.De Vita, M.Orditura, A.Auriemma, S.Infusino, A.Roscigno, G.Catalano. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5:649-52; PMID:9538169
42. A.J.Lambeck, A.P.Crijns, N.Leffers, W.J.Sluiter, K.A.ten Hoor, M.Braid, A.G.van der Zee, T.Daemen, H.W.Nijman, W.M.Kast. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007; 13:2385-91; PMID:17438097; http://dx.doi.org/10.1158/1078-0432.CCR-06-1828
43. C.Tempfer, H.Zeisler, G.Sliutz, G.Haeusler, E.Hanzal, C.Kainz. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997; 66:27-30; PMID:9234916; http://dx.doi.org/10.1006/gyno.1997.4726
44. G.Scambia, U.Testa, P.B.Panici, R.Martucci, E.Foti, M.Petrini, M.Amoroso, V.Masciullo, C.Peschle, S.Mancuso. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994; 57:318-23; PMID:8168990; http://dx.doi.org/10.1002/ijc.2910570305
45. L.M.Pedersen, T.W.Klausen, U.H.Davidsen, H.E.Johnsen. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005; 84:510-6; PMID:15834569; http://dx.doi.org/10.1007/s00277-005-1020-x
46. A.Novotny, K.Emmanuel, H.Bartels, J.R.Siewert, B.Holzmann. [Indicators for early prediction of outcome in sepsis]. Chirurg 2005; 76:837-44; PMID:16094522; http://dx.doi.org/10.1007/s00104-005-1077-z
47. M.Rodriguez-Gaspar, F.Santolaria, A.Jarque-Lopez, E.Gonzalez-Reimers, A.Milena, M.J.de la Vega, E.Rodriguez-Rodriguez, J.L.Gomez-Sirvent. Prognostic value of cytokines in SIRS general medical patients. Cytokine 2001; 15:232-6; PMID:11563884; http://dx.doi.org/10.1006/cyto.2001.0932
48. A.Viallon, S.Guyomarc'h, O.Marjollet, C.Berger, A.Carricajo, F.Robert, S.Laporte, C.Lambert, Y.Page, F.Zeni et al. Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. Eur J Emerg Med 2008; 15:26-33; PMID:18180663; http://dx.doi.org/10.1097/MEJ.0b013e3280ec539b
49. H.P.Wu, C.K.Chen, K.Chung, J.C.Tseng, C.C.Hua, Y.C.Liu, D.Y.Chuang, C.H.Yang. Serial cytokine levels in patients with severe sepsis. Inflamm Res 2009; 58(7):385-93; PMID:19262987; http://dx.doi.org/10.1007/s00011-009-0003-0
50. R.A.Ghani, S.Zainudin, N.Ctkong, A.F.Rahman, S.R.Wafa, M.Mohamad, M.R.Manaf, R.Ismail. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 2006; 11:386-93; PMID:17014550; http://dx.doi.org/10.1111/j.1440-1797.2006.00600.x
51. A.B.Groeneveld, A.N.Tacx, A.W.Bossink, G.J.van Mierlo, C.E.Hack. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003; 106:106-15; PMID:12672401; http://dx.doi.org/10.1016/S1521-6616(02)00025-6
52. R.T.Patel, K.I.Deen, D.Youngs, J.Warwick, M.R.Keighley. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81:1306-8; PMID:7953393; http://dx.doi.org/10.1002/bjs.1800810914
53. A.Bencosme, A.Warner, D.Healy, C.Verme. Prognostic potential of cytokines, nitrates, and APACHE II score in sepsis. Ann Clin Lab Sci 1996; 26:426-32; PMID:8879360
54. A.Oberholzer, S.M.Souza, S.K.Tschoeke, C.Oberholzer, A.Abouhamze, J.P.Pribble, L.L.Moldawer. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005; 23:488-93; PMID:15897799; http://dx.doi.org/10.1097/01.shk.0000163802.46355.59
55. G.P.Dunn, L.J.Old, R.D.Schreiber. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017
56. B.Vizio, A.Novarino, A.Giacobino, C.Cristiano, A.Prati, L.Ciuffreda, G.Montrucchio, G.Bellone. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med 2012; 4:70-8; PMID:23060925; http://dx.doi.org/10.3892%2Fetm.2012.553
57. C.Su, C.Zhou, S.Zhou, J.Xu. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 2011; 28:1453-7; PMID:20714944; http://dx.doi.org/10.1007/s12032-010-9645-6
58. E.B.Candido, L.M.Silva, A.T.Carvalho, R.M.Lamaita, R.M.Filho, B.D.Cota, A.L.da Silva-Filho. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci 2013; 20:828-37; PMID:23239818; http://dx.doi.org/10.1177/1933719112466299
59. K.A.Kwon, S.H.Kim, S.Y.Oh, S.Lee, J.Y.Han, K.H.Kim, R.Y.Goh, H.J.Choi, K.J.Park, M.S.Roh et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010; 10:203; PMID:20465852; http://dx.doi.org/10.1186/1471-2407-10-203
60. S.Svobodova, O.Topolcan, L.Holubec, Jr., M.Levy, L.Pecen, S.Svacina. Parameters of biological activity in colorectal cancer. Anticancer Res 2011; 31:373-8; PMID:21273626
61. S.I.Labidi, C.Menetrier-Caux, S.Chabaud, C.Chassagne, C.Sebban, T.Gargi, P.Biron, J.Y.Blay, H.Ghesquieres. Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival. Ann Hematol 2010; 89:25-33; PMID:19582455; http://dx.doi.org/10.1007/s00277-009-0777-8
62. M.Groblewska, B.Mroczko, U.Wereszczynska-Siemiatkowska, B.Kedra, M.Lukaszewicz, A.Baniukiewicz, M.Szmitkowski. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008; 46:1423-8; PMID:18844497; http://dx.doi.org/10.1515/CCLM.2008.278
63. M.Lukaszewicz-Zajac, B.Mroczko, M.Gryko, B.Kedra, M.Szmitkowski. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2011; 11:89-96; PMID:20938721; http://dx.doi.org/10.1007/s10238-010-0114-5
64. F.Ozdemir, F.Aydin, M.Yilmaz, H.Kavgaci, O.Bektas, M.N.Yavuz, A.A.Yavuz. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res 2004; 23:485-8; PMID:15595640
65. M.M.Walther, B.Johnson, D.Culley, R.Shah, J.Weber, D.Venzon, J.C.Yang, W.M.Linehan, S.A.Rosenberg. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998; 159:718-22; PMID:9474133; http://dx.doi.org/10.1016/S0022-5347(01)63709-1
66. M.S.Vuoristo, P.Kellokumpu-Lehtinen, S.Laine, L.M.Parvinen, M.Hahka-Kemppinen, M.Korpela, E.Kumpulainen. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res 2000; 10:237-41; PMID:10890377; http://dx.doi.org/10.1097/00008390-200010030-00005
67. Y.Ren, H.T.Tsui, R.T.Poon, I.O.Ng, Z.Li, Y.Chen, G.Jiang, C.Lau, W.C.Yu, M.Bacher et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer J Int Du Cancer 2003; 107:22-9; PMID:12925952; http://dx.doi.org/10.1002/ijc.11287
68. V.Marin, F.Montero-Julian, S.Gres, P.Bongrand, C.Farnarier, G.Kaplanski. Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-α-converting enzyme (TACE) type. Eur J Immunol 2002; 32:2965-70; PMID:12355450; http://dx.doi.org/10.1002/1521-4141(2002010)32:10%3c2965::AID-IMMU2965%3e3.0.CO;2-V
69. J.Scheller, N.Ohnesorge, S.Rose-John. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006; 63:321-9; PMID:16640655; http://dx.doi.org/10.1111/j.1365-3083.2006.01750.x
70. R.Atreya, M.F.Neurath. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28:187-96; PMID:16129903; http://dx.doi.org/10.1385/CRIAI:28:3:187
71. D.S.Hong, L.S.Angelo, R.Kurzrock. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110:1911-28; PMID:17849470; http://dx.doi.org/10.1002/cncr.22999
72. S.O'Reilly, M.Ciechomska, R.Cant, T.Hugle, J.M.van Laar. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23:99-107; PMID:22561547; http://dx.doi.org/10.1016/j.cytogfr.2012.04.003
73. J.Gauldie, C.Richards, D.Harnish, P.Lansdorp, H.Baumann. Interferon β 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251-5; PMID:2444978; http://dx.doi.org/10.1073/pnas.84.20.7251
74. T.Korn, E.Bettelli, M.Oukka, V.K.Kuchroo. IL-17 and Th17 Cells. Ann Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev.immunol.021908.132710
75. S.C.Afford, J.Pongracz, R.A.Stockley, J.Crocker, D.Burnett. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 1992; 267:21612-6; PMID:1400472
76. A.Mantovani, G.Germano, F.Marchesi, M.Locatelli, S.K.Biswas. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011; 41:2522-5; PMID:21952810; http://dx.doi.org/10.1002/eji.201141894
77. H.Roca, Z.S.Varsos, S.Sud, M.J.Craig, C.Ying, K.J.Pienta. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284:34342-54; PMID:19833726; http://dx.doi.org/10.1074/jbc.M109.042671
78. J.Zhang, L.Patel, K.J.Pienta. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95:31-53; PMID:21075328; http://dx.doi.org/10.1016/B978-0-12-385071-3.00003-4
79. F.Balkwill. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540-50; PMID:15229479; http://dx.doi.org/10.1038/nrc1388
80. R.P.Negus, G.W.Stamp, J.Hadley, F.R.Balkwill. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997; 150:1723-34; PMID:9137096
81. J.Van Snick. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-78; PMID:2188664; http://dx.doi.org/10.1146/annurev.iy.08.040190.001345
82. T.Kinoshita, H.Ito, C.Miki. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85:2526-31; PMID:10375098; http://dx.doi.org/10.1002/(SICI)1097-0142(19990615)85:12%3c2526::AID-CNCR6%3e3.0.CO;2-3
83. M.F.Chen, P.T.Chen, M.S.Lu, P.Y.Lin, W.C.Chen, K.D.Lee. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013; 12:26; PMID:23561329; http://dx.doi.org/10.1186/1476-4598-12-26
84. C.W.Wu, S.R.Wang, M.F.Chao, T.C.Wu, W.Y.Lui, F.K.P'Eng, C.W.Chi. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996; 91:1417-22; PMID:8678006
85. T.Fukuyama, Y.Ichiki, S.Yamada, Y.Shigematsu, T.Baba, Y.Nagata, M.Mizukami, M.Sugaya, M.Takenoyama, T.Hanagiri et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci 2007; 98:1048-54.; PMID:17511773; http://dx.doi.org/10.1111/j.1349-7006.2007.00507.x
86. G.Bellone, C.Smirne, F.A.Mauri, E.Tonel, A.Carbone, A.Buffolino, L.Dughera, A.Robecchi, M.Pirisi, G.Emanuelli. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55:684-98; PMID:16094523; http://dx.doi.org/10.1007/s00262-005-0047-0
87. K.C.Chow, S.H.Chiou, S.P.Ho, M.H.Tsai, C.L.Chen, L.S.Wang, K.H.Chi. The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep 2003; 10:813-9; PMID:12792728
88. Y.C.Chung, Y.L.Chaen, C.P.Hsu. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 2006; 26:3905-11; PMID:17094421
89. J.Y.Yoon, S.Lafarge, D.Dawe, S.Lakhi, R.Kumar, C.Morales, A.Marshall, S.B.Gibson, J.B.Johnston. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:1735-42; PMID:22475215; http://dx.doi.org/10.3109/10428194.2012.666662
90. G.W.Lamb, P.A.McArdle, S.Ramsey, A.M.McNichol, J.Edwards, M.Aitchison, D.C.McMillan. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008; 102:756-61; PMID:18384626; http://dx.doi.org/10.1111/j.1464-410X.2008.07666.x
91. A.G.Moses, J.Maingay, K.Sangster, K.C.Fearon, J.A.Ross. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009; 21:1091-5; PMID:19288013; http://dx.doi.org/10.3892/or_00000328
92. M.E.Martignoni, P.Kunze, W.Hildebrandt, B.Kunzli, P.Berberat, T.Giese, O.Kloters, J.Hammer, M.W.Buchler, N.A.Giese et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005; 11:5802-8; PMID:16115919; http://dx.doi.org/10.1158/1078-0432.CCR-05-0185
93. O.Gallo, A.M.Gori, M.Attanasio, F.Martini, B.Giusti, M.Boddi, E.Gallina, O.Fini, R.Abbate. Interleukin-1 β and interleukin-6 release by peripheral blood monocytes in head and neck cancer. Br J Cancer 1993; 68:465-8; PMID:8353036; http://dx.doi.org/10.1038/bjc.1993.371
94. G.Monfrecola, F.Gaudiello, T.Cirillo, G.Fabbrocini, A.Balato, S.Lembo. Nicotinamide downregulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-α gene expression in HaCaT keratinocytes after ultraviolet B irradiation. Clin Exp Dermatol 2013; 38:185-8; PMID:23397947; http://dx.doi.org/10.1111/ced.12018
95. C.Yue, X.You, L.Zhao, H.Wang, F.Tang, F.Zhang, X.Zhang, W.He. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30:1553-7; PMID:19847432; http://dx.doi.org/10.1007/s00296-009-1179-x
96. S.Dhillon. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. BioDrugs 2014; 28:75-106; PMID:24255004; http://dx.doi.org/10.1007/s40259-013-0076-8
97. E.Assier, M.C.Boissier, J.M.Dayer. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010; 77:532-6; PMID:20869898; http://dx.doi.org/10.1016/j.jbspin.2010.07.007
98. N.A.Schultz, I.J.Christensen, J.Werner, N.Giese, B.V.Jensen, O.Larsen, J.K.Bjerregaard, P.Pfeiffer, D.Calatayud, S.E.Nielsen et al. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One 2013; 8:e67059; PMID:23840582; http://dx.doi.org/10.1371/journal.pone.0067059
99. S.Mitsunaga, M.Ikeda, S.Shimizu, I.Ohno, J.Furuse, M.Inagaki, S.Higashi, H.Kato, K.Terao, A.Ochiai. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108:2063-9; PMID:23591198; http://dx.doi.org/10.1038/bjc.2013.174
100. A.Arshad, W.Y.Chung, W.Steward, M.S.Metcalfe, A.R.Dennison. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 2013; 15:428-32; PMID:23458624; http://dx.doi.org/10.1111/hpb.12002
101. B.Mroczko, M.Groblewska, M.Gryko, B.Kedra, M.Szmitkowski. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010; 24:256-61; PMID:20626020; http://dx.doi.org/10.1002/jcla.20395
102. P.Ravishankaran, R.Karunanithi. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011; 9:18; PMID:21294915; http://dx.doi.org/10.1186/1477-7819-9-18
103. M.Fuksiewicz, M.Kowalska, B.Kotowicz, M.Rubach, M.Chechlinska, T.Pienkowski, J.Kaminska. Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer. Clin Chem Lab Med 2010; 48:1481-6; PMID:20578967; http://dx.doi.org/10.1515/CCLM.2010.278
104. H.Bozcuk, G.Uslu, M.Samur, M.Yildiz, T.Ozben, M.Ozdogan, M.Artac, H.Altunbas, I.Akan, B.Savas. Tumour necrosis factor-α, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004; 27:58-65; PMID:15242694; http://dx.doi.org/10.1016/j.cyto.2004.04.002
105. T.Bachelot, I.Ray-Coquard, C.Menetrier-Caux, M.Rastkha, A.Duc, J.Y.Blay. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88:1721-6; PMID:12771987; http://dx.doi.org/10.1038/sj.bjc.6600956
106. R.Salgado, S.Junius, I.Benoy, P.Van Dam, P.Vermeulen, E.Van Marck, P.Huget, L.Y.Dirix. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer J Int Du Cancer 2003; 103:642-6; PMID:12494472; http://dx.doi.org/10.1002/ijc.10833
107. G.J.Zhang, I.Adachi. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19:1427-32; PMID:10365118
108. W.Dean-Colomb, K.R.Hess, E.Young, T.G.Gornet, B.C.Handy, S.L.Moulder, N.Ibrahim, L.Pusztai, D.Booser, V.Valero et al. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 2013; 137:631-6; PMID:23242617; http://dx.doi.org/10.1007/s10549-012-2374-0
109. J.Shimazaki, Y.Goto, K.Nishida, T.Tabuchi, G.Motohashi, H.Ubukata. In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression. Oncology 2013; 84:356-61; PMID:23689116; http://dx.doi.org/10.1159/000350836
110. K.Y.Yeh, Y.Y.Li, L.L.Hsieh, C.H.Lu, W.C.Chou, C.C.Liaw, R.P.Tang, S.K.Liao. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 2010; 40:580-7; PMID:20194250; http://dx.doi.org/10.1093/jjco/hyq010
111. N.I.Nikiteas, N.Tzanakis, M.Gazouli, G.Rallis, K.Daniilidis, G.Theodoropoulos, A.Kostakis, G.Peros. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11:1639-43; PMID:15786541; http://dx.doi.org/10.3748/wjg.v11.i11.1639
112. Y.C.Chung, Y.F.Chang. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83:222-6; PMID:12884234; http://dx.doi.org/10.1002/jso.10269
113. C.Belluco, D.Nitti, M.Frantz, P.Toppan, D.Basso, M.Plebani, M.Lise, J.M.Jessup. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000; 7:133-8; PMID:10761792; http://dx.doi.org/10.1007/s10434-000-0133-7
114. Y.Liu, M.D.Starr, A.Bulusu, H.Pang, N.S.Wong, W.Honeycutt, A.Amara, H.I.Hurwitz, A.B.Nixon. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013; 2:234-42; PMID:23634291; http://dx.doi.org/10.1002/cam4.71
115. R.Sharma, M.Zucknick, R.London, M.Kacevska, C.Liddle, S.J.Clarke. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008; 7:331-7; PMID:18794066; http://dx.doi.org/10.3816/CCC.2008.n.044
116. M.Lukaszewicz-Zajac, B.Mroczko, M.Kozlowski, J.Niklinski, J.Laudanski, M.Szmitkowski. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 2012; 25:242-9; PMID:21895853; http://dx.doi.org/10.1111/j.1442-2050.2011.01242.x
117. W.Hao, Y.Zhu, H.Zhou. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013; 30:333; PMID:23269580; http://dx.doi.org/10.1007/s12032-012-0333-6
118. G.Scambia, U.Testa, P.Benedetti Panici, E.Foti, R.Martucci, A.Gadducci, A.Perillo, V.Facchini, C.Peschle, S.Mancuso. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995; 71:354-6; PMID:7841052; http://dx.doi.org/10.1038/bjc.1995.71
119. Y.S.Wang, L.Y.Miao, L.Liu, H.R.Cai, J.J.Ding, S.X.Ren, C.C.Zhou, G.Schmid-Bindert. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl) 2013; 126:3931-5; PMID:24157160; http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130578
120. C.H.Chang, C.F.Hsiao, Y.M.Yeh, G.C.Chang, Y.H.Tsai, Y.M.Chen, M.S.Huang, H.L.Chen, Y.J.Li, P.C.Yang et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977-85; PMID:23034889; http://dx.doi.org/10.1002/ijc.27892
121. H.Ujiie, M.Tomida, H.Akiyama, Y.Nakajima, D.Okada, N.Yoshino, Y.Takiguchi, H.Tanzawa. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 2012; 32:3251-8; PMID:22843899
122. K.Sanchez-Lara, J.G.Turcott, E.Juarez, P.Guevara, C.Nunez-Valencia, L.F.Onate-Ocana, D.Flores, O.Arrieta. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer 2012; 64:526-34; PMID:22489794; http://dx.doi.org/10.1080/01635581.2012.668744
123. E.Koh, T.Iizasa, H.Yamaji, Y.Sekine, K.Hiroshima, I.Yoshino, T.Fujisawa. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol 2012; 20:233-9; PMID:22334615; http://dx.doi.org/10.1177/1066896911436274
124. C.Dehing-Oberije, H.Aerts, S.Yu, D.De Ruysscher, P.Menheere, M.Hilvo, H.van der Weide, B.Rao, P.Lambin. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011; 81:360-8; PMID:20888135; http://dx.doi.org/10.1016/j.ijrobp.2010.06.011
125. N.Songur, B.Kuru, F.Kalkan, C.Ozdilekcan, H.Cakmak, N.Hizel. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90:196-200; PMID:15237582
126. L.Enewold, L.E.Mechanic, E.D.Bowman, Y.L.Zheng, Z.Yu, G.Trivers, A.J.Alberg, C.C.Harris. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18:215-22; PMID:19124500; http://dx.doi.org/10.1158/1055-9965.EPI-08-0705
127. F.Martin, F.Santolaria, N.Batista, A.Milena, E.Gonzalez-Reimers, M.J.Brito, J.Oramas. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-6; PMID:10080883; http://dx.doi.org/10.1006/cyto.1998.0398
128. N.Katsumata, K.Eguchi, M.Fukuda, N.Yamamoto, Y.Ohe, F.Oshita, T.Tamura, T.Shinkai, N.Saijo. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996; 2:553-9; PMID:9816203
129. J.Kaminska, M.Kowalska, B.Kotowicz, M.Fuksiewicz, M.Glogowski, E.Wojcik, M.Chechlinska, J.Steffen. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006; 70:115-25; PMID:16645324; http://dx.doi.org/10.1159/000093002
130. E.Wojcik, J.Jakubowicz, P.Skotnicki, B.Sas-Korczynska, J.K.Kulpa. IL-6 and VEGF in small cell lung cancer patients. Anticancer Res 2010; 30:1773-8; PMID:20592377
131. L.G.Necula, M.Chivu-Economescu, E.L.Stanciulescu, C.Bleotu, S.O.Dima, I.Alexiu, A.Dumitru, G.Constantinescu, I.Popescu, C.C.Diaconu. IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis 2012; 21:23-9; PMID:22457856
132. D.K.Kim, S.Y.Oh, H.C.Kwon, S.Lee, K.A.Kwon, B.G.Kim, S.G.Kim, S.H.Kim, J.S.Jang, M.C.Kim et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9:155; PMID:19457231; http://dx.doi.org/10.1186/1471-2407-9-155
133. M.Ikeguchi, T.Hatada, M.Yamamoto, T.Miyake, T.Matsunaga, Y.Fukumoto, Y.Yamada, K.Fukuda, H.Saito, S.Tatebe. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009; 12:95-100; PMID:19562463; http://dx.doi.org/10.1007/s10120-009-0509-8
134. T.Ashizawa, R.Okada, Y.Suzuki, M.Takagi, T.Yamazaki, T.Sumi, T.Aoki, S.Ohnuma. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005; 8:124-31; PMID:15864720; http://dx.doi.org/10.1007/s10120-005-0315-x
135. F.De Vita, C.Romano, M.Orditura, G.Galizia, E.Martinelli, E.Lieto, G.Catalano. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45-52; PMID:11177580; http://dx.doi.org/10.1089/107999001459150
136. M.Yoshitomi, S.Yutani, S.Matsueda, T.Ioji, N.Komatsu, S.Shichijo, A.Yamada, K.Itoh, T.Sasada, H.Kinoshita. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463-9; PMID:22969912; http://dx.doi.org/10.3892/etm.2011.424
137. H.T.Tran, Y.Liu, A.J.Zurita, Y.Lin, K.L.Baker-Neblett, A.M.Martin, R.A.Figlin, T.E.Hutson, C.N.Sternberg, R.G.Amado et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13:827-37; PMID:22759480; http://dx.doi.org/10.1016/S1470-2045(12)70241-3
138. A.J.Montero, C.M.Diaz-Montero, R.E.Millikan, J.Liu, K.A.Do, S.Hodges, E.Jonasch, B.W.McIntyre, P.Hwu, N.Tannir. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival. Ann Oncol 2009; 20:1682-7; PMID:19541791; http://dx.doi.org/10.1093/annonc/mdp054
139. M.Guida, A.Casamassima, G.Monticelli, M.Quaranta, G.Colucci. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007; 5:51; PMID:17953739; http://dx.doi.org/10.1186/1479-5876-5-51
140. S.Negrier, D.Perol, C.Menetrier-Caux, B.Escudier, M.Pallardy, A.Ravaud, J.Y.Douillard, C.Chevreau, C.Lasset, J.Y.Blay. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004; 22:2371-8; PMID:15197198; http://dx.doi.org/10.1200/JCO.2004.06.121
141. J.P.Kallio, T.L.Tammela, A.T.Marttinen, P.L.Kellokumpu-Lehtinen. Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res 2001; 20:523-8; PMID:11876546
142. D.Favaro, M.Santarosa, M.Quaia, E.Galligioni. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997; 3:51-8; PMID:21227060; http://dx.doi.org/10.1016/S1078-1439(97)00036-7
143. S.A.Duffy, J.M.Taylor, J.E.Terrell, M.Islam, Y.Li, K.E.Fowler, G.T.Wolf, T.N.Teknos. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113:750-7; PMID:18536030; http://dx.doi.org/10.1002/cncr.23615
144. D.J.George, S.Halabi, T.F.Shepard, B.Sanford, N.J.Vogelzang, E.J.Small, P.W.Kantoff. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11:1815-20; PMID:15756004; http://dx.doi.org/10.1158/1078-0432.CCR-04-1560
145. V.Michalaki, K.Syrigos, P.Charles, J.Waxman. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. British J Cancer 2004; 90:2312-6; PMID:15150588; http://dx.doi.org/10.1038/sj.bjc.6601814
146. J.Nakashima, M.Tachibana, Y.Horiguchi, M.Oya, T.Ohigashi, H.Asakura, M.Murai. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6:2702-6; PMID:10914713
147. B.Andrews, S.F.Shariat, J.H.Kim, T.M.Wheeler, K.M.Slawin, S.P.Lerner. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002; 167:1475-81; PMID:11832773; http://dx.doi.org/10.1016/S0022-5347(05)65348-7
148. P.Rutkowski, J.Kaminska, M.Kowalska, W.Ruka, J.Steffen. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003; 84:151-9; PMID:14598359; http://dx.doi.org/10.1002/jso.10305
149. P.Rutkowski, J.Kaminska, M.Kowalska, W.Ruka, J.Steffen. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer J Int Du Cancer 2002; 100:463-71; PMID:12115531; http://dx.doi.org/10.1002/ijc.10496
150. L.Hoejberg, L.Bastholt, J.S.Johansen, I.J.Christensen, J.Gehl, H.Schmidt. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 2012; 22:287-93; PMID:22617301; http://dx.doi.org/10.1097/CMR.0b013e3283550aa5
151. M.Guida, A.Riccobon, G.Biasco, A.Ravaioli, A.Casamassima, A.Freschi, M.D.Palma, E.Galligioni, R.Nortilli, V.Chiarion-Sileni et al. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 2006; 16:317-23; PMID:16845327; http://dx.doi.org/10.1097/01.cmr.0000200491.00841.5f
152. R.Mouawad, C.Soubrane, O.Rixe, D.Khayat, J.P.Spano. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res 2006; 16:335-40; PMID:16845329
153. F.Tas, H.Oguz, A.Argon, D.Duranyildiz, H.Camlica, V.Yasasever, E.Topuz. The value of serum levels of IL-6, TNF-α, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Medical Oncol 2005; 22:241-6; PMID:16110135; http://dx.doi.org/10.1385/MO:22:3:241
154. C.Soubrane, O.Rixe, J.B.Meric, D.Khayat, R.Mouawad. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199-204; PMID:15917702; http://dx.doi.org/10.1097/00008390-200506000-00009
155. R.O.Casasnovas, N.Mounier, P.Brice, M.Divine, F.Morschhauser, J.Gabarre, J.Y.Blay, L.Voillat, P.Lederlin, A.Stamatoullas et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25:1732-40; PMID:17389336; http://dx.doi.org/10.1200/JCO.2006.08.1331
156. H.A.Preti, F.Cabanillas, M.Talpaz, S.L.Tucker, J.F.Seymour, R.Kurzrock. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127:186-94; PMID:9245223; http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002
157. J.F.Seymour, M.Talpaz, F.Cabanillas, M.Wetzler, R.Kurzrock. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13:575-82; PMID:7884418
158. M.Giachelia, M.T.Voso, M.C.Tisi, M.Martini, V.Bozzoli, G.Massini, F.D'Alo, L.M.Larocca, G.Leone, S.Hohaus. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012; 53:411-6; PMID:21902578; http://dx.doi.org/10.3109/10428194.2011.621566
159. E.Fabre-Guillevin, R.Tabrizi, V.Coulon, A.Monnereau, H.Eghbali, I.Soubeyran, P.Soubeyran. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47:603-11; PMID:16690518; http://dx.doi.org/10.1080/10428190500361029
160. M.el-Far, M.Fouda, R.Yahya, H.el-Baz. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 2004; 60:253-8; PMID:15957243; http://dx.doi.org/10.1007/BF03167070
161. N.Niitsu, M.Okamato, H.Nakamine, T.Yoshino, J.Tamaru, S.Nakamura, M.Higashihara, M.Hirano. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68:91-100; PMID:12038454; http://dx.doi.org/10.1034/j.1600-0609.2002.01609.x
162. R.Kurzrock, J.Redman, F.Cabanillas, D.Jones, J.Rothberg, M.Talpaz. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53:2118-22; PMID:8481913
163. A.Inagaki, T.Ishida, T.Ishii, H.Komatsu, S.Iida, J.Ding, K.Yonekura, S.Takeuchi, Y.Takatsuka, A.Utsunomiya et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006; 118:3054-61; PMID:16425276; http://dx.doi.org/10.1002/ijc.21688
164. M.Yamamura, Y.Yamada, S.Momita, S.Kamihira, M.Tomonaga. Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998; 100:129-34; PMID:9450801; http://dx.doi.org/10.1046/j.1365-2141.1998.00538.x
165. R.A.Egler, S.M.Burlingame, J.G.Nuchtern, H.V.Russell. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 2008; 14:7028-34; PMID:18980999; http://dx.doi.org/10.1158/1078-0432.CCR-07-5017